These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Glutathione-S transferase-pi expression in non small cell lung cancer in the assessment of response to chemotherapy.
    Author: Unsal M, Akpolat I, Kandemir B.
    Journal: Saudi Med J; 2003 May; 24(5):493-8. PubMed ID: 12847624.
    Abstract:
    OBJECTIVE: To determine the relation of glutathione-S transferase-pi (GST-pi) expression and cisplatin resistance in non small cell lung cancer (NSCLC). METHODS: This study was carried out on 61 patients who were admitted to Chest Diseases Clinic, Ondokuz Mayis University, Samsun, Turkey, from 1997 to 1999. Twenty-seven NSCLC patients out of 61 lung cancer cases whose biopsy specimens were evaluated for GST-pi, received multiagent chemotherapy including cisplatin. The correlations between GST-pi expression and age, sex, performance score, histology, stage of the disease and response to chemotherapy were investigated. RESULTS: There was a significant correlation between GST-pi expression and the histological type of the disease (p<0.05). However, no significant relation was found with age, sex, performance score or stage of the disease (p>0.05). Glutathione-S transferase-pi staining characteristics of the 27 patients receiving chemotherapy were: less than 10% in 3 patients (11.1%), 10-50% in 9 patients (33.3%) and more than 50% in 15 patients (55.5%). One of the 3 patients (33.3%) with GST-pi staining percentage of less than 10%, 3 of 9 patients (33.3%) with staining percentage of 10-50% and 4 out of 15 patients (26.6%) with staining percentage of more than 50% had an objective response to chemotherapy. No significant correlation was found between GST-pi expression and response to chemotherapy in the 3 groups (p>0.05). CONCLUSION: Glutathione-S transferase-pi expression might not always predict the response to combination chemotherapy regimens containing cisplatin. Several other mechanisms may play a role in cisplatin-resistance.
    [Abstract] [Full Text] [Related] [New Search]